| Code | CSB-RA023978MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to BI-1808, designed to target TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily Member 1B), also known as TNFR2 or CD120b. TNFRSF1B is a cell surface receptor that plays a critical role in immune regulation by mediating TNF-alpha signaling pathways. Unlike TNFRSF1A, which primarily triggers pro-inflammatory and apoptotic responses, TNFRSF1B promotes cell survival, proliferation, and tissue repair. This receptor is preferentially expressed on regulatory T cells, myeloid-derived suppressor cells, and certain tumor cells, making it a significant target in cancer immunology and inflammatory disease research. Dysregulated TNFRSF1B signaling has been implicated in various malignancies, autoimmune disorders, and chronic inflammatory conditions.
BI-1808 is an investigational therapeutic antibody that selectively antagonizes TNFRSF1B, demonstrating potential to modulate immunosuppressive tumor microenvironments and enhance anti-tumor immunity. This biosimilar provides researchers with a valuable tool for studying TNFR2-mediated immune mechanisms, investigating therapeutic strategies in oncology and immunology, and exploring the receptor's role in disease pathogenesis.
There are currently no reviews for this product.